This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA.

In patients with diabetes and multivessel coronary artery disease (MVD), the ultra-thin biodegradable polymer sirolimus-eluting stent (Supraflex Cruz, SMT) demonstrated comparable procedural success and safety outcomes to the durable polymer everolimus-eluting stent (Xience, Abbott) when used alongside optimal medical therapy, according to results from the TUXEDO-2 trial presented by Dr. Upendra Kaul at TCT 2025.

The TUXEDO-2 (Ultra-Thin strUt versus XiencE in a Diabetic pOpulation with Multi-vessel Disease–2) India study is the largest randomized trial to date comparing new-generation drug-eluting stents (DES) in an exclusively diabetic, high-risk population with ex

See Full Page